For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Novartis Forms Regional Collab in Nagasaki for CV, Respiratory Diseases
April 19, 2022
- Shionogi, NEC Pair Up for Novel Hepatitis B Therapeutic Vaccine Research
April 19, 2022
- Nippon Boehringer Ingelheim Logs 6.7% Sales Rise in 2021
April 19, 2022
- JCR, Teijin Ditch Regenerative Medicine Deal after Japan PI/II Flop
April 19, 2022
- Otsuka Grabs Rights to Osaka University’s New Antitumor Antibody
April 18, 2022
- Mediceo Gets 6-Month Suspension from National Hospital Organization Bids
April 18, 2022
- Female Manager Ratio at Japan Drug Makers Finally Hits 10%, Foreign Peers Near 25%: Jiho Poll
April 15, 2022
- Astellas’ Padcev Receives Bladder Cancer Nod in Europe
April 15, 2022
- Bayer Yakuhin Sees 2021 Sales Skid 0.6% but Still Reach Target, Retains Spot in Top 10
April 15, 2022
- Shionogi Unit, LPIXEL to Study AI-Based Drug Discovery Tech for Infectious Diseases
April 15, 2022
- Takeda’s HAE Med Takhzyro Hits Targets in Global PIII for Pediatric Patients
April 14, 2022
- Teratogenicity Data for COVID Pill Already Submitted to Japan Regulators: Shionogi
April 14, 2022
- Lumakras Nears Japan Market, Amgen Eyes Simultaneous Launch with US for Next 5 Oncology Drugs: EVP
April 14, 2022
- Innovative Brands to Drive Return to Growth at Lilly Japan after 2 Years of Decline: President
April 13, 2022
- Myovant’s Myfembree Label Expansion Plan Stumbles in FDA Review
April 13, 2022
- Opdivo Gets Adjuvant Nod for Urothelial Cancer in Taiwan
April 13, 2022
- Shionogi’s COVID Pill Might Not Be Recommended for Pregnant Women over Birth Defect Risk
April 13, 2022
- Daiichi Sankyo Espha Launches Follow-On AG for Diart
April 13, 2022
- Jury Finds Enhertu Infringes Seagen Patent, Awards US$41.8 Million in Damages
April 12, 2022
- CEPI to Fund NEC’s AI-Based Coronavirus Vaccine Development
April 12, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…